Allergan

Sep 04, 2024

Obesity and diabetes are a global epidemic contributing to an increasing prevalence of related systemic disorders, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Nonalcoholic Steatohepatitis is a subtype of NAFLD (Nonalcoholic Fatty Liver disease) that is characterized...

Sep 04, 2024

Nonalcoholic Steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by liver inflammation and damage due to fat accumulation. Unlike simple fatty liver, NASH can progress to serious conditions such as fibrosis, cirrhosis, and liver failure. This chronic liver disease is i...

Jun 21, 2021

Presbyopia is the gradual loss of near-focusing ability that occurs with age—a condition that occurs when people get older and prevails as a quite common one in many individuals. The reasons for this lack of accommodation power are undetermined. It is commonly assumed that this is due to the lens being less elastic...

Aug 17, 2020

The Gastroparesis market size in the 7MM was found to be USD 3,170.01 million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in the mid-/ late-stage clinical development and rising gastroparesis prevalence. Gastroparesis or Delayed gastric emp...

Feb 17, 2020

With no effective cure in Wet Age-related macular degeneration (Wet AMD) treatment market, the need of new therapies that can not only slow down the progression of the vision loss but also kill the cause behind the degeneration of the macula. The present treatment approach requires intravitreal injection of anti-VE...

Dec 24, 2019

Roche has entered into a licensing partnership with Sarepta Therapeutics worth USD 1.15 Billion.  Roche has agreed to license in Sarepta’s gene therapy ‘SRP-9001’ for Duchenne muscular dystrophy (DMD), though which Roche will gain access to exclusive rights to it globally except in the US.  As per t...

Nov 14, 2019

AbbVie has traded off its bonds worth USD 30 Billion to finance the purchase of the Allergan.   AbbVie this year in June has agreed to buy Allergan for USD 63 Billion, which is one of the largest deals this year. The acquisition will help AbbVie to diversify its drug portfolio which mostly revolves around H...

Oct 07, 2019

The World Health Organization’s disability rating for migraine ranks it as the 19th most common reason for disability. According to the Migraine Trust Organization, Migraine is ranked as the 7th most disabling disease in the world (a cause for a loss of 2.9% of all years of life lost to disability/YLDs). The ...

Sep 10, 2019

Daiichi Sankyo announced the submission of a New Drug Application (NDA) of DS-8201 to Japan's Ministry of Health, Labour and Welfare (MHLW). DS-8201 [fam-] trastuzumab deruxtecan), is an investigational antibody-drug conjugate (ADC) designed to deliver cytotoxic chemotherapy to cancer cells via a human epiderma...

Aug 02, 2019

Gastroparesis is a condition that affects the movement of the food in the stomach and intestines and causes distress leading to bloating, nausea, and heartburn. If the condition is due to Diabetes in the patients, it is called Diabetic Gastroparesis. According to the American Diabetes Association (ADA), Gastropares...